← All themes

Theme

Biotech

Every analyzed stock in Biotech — 657 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Biotech risk

Near-term vs. long-term risk for this theme

⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months

39 /100 Moderate ▼ -3 slight

Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history

61 /100 High ◆ flat

▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.

Inside the "right now" score — a 45 / 30 / 25 blend · 118 stocks valued

Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.

35 Moderate

Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 118 stocks.

39 Moderate

Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.

45 Elevated

Smart money — the three inputs

Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.

48.9%

Elevated

Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.

55%

Elevated

Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.

30%

Moderate

Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 552 stocks (full universe); short-selling is market-wide.

Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.

Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest

This week in Biotech

Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →

The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…

Arcutis Biotherapeutics, Inc.

Deeply overvalued

Healthcare Risk 64 · High

Premium +436% Return to IV: -81.3%

Market implies +23.5%/yr vs model +15.0% · above model

ARTELO BIOSCIENCES, INC.

Healthcare Risk 31 · Moderate

Limited data — see page

Artiva Biotherapeutics, Inc.

Healthcare Risk 38 · Moderate

Market implies +116.4%/yr vs model +15.0% · above model

Deeply undervalued

Healthcare Risk 33 · Moderate

Discount 68% Return to IV: +211.7%

Market implies -20.1%/yr vs model +48.8% · below model

Aspire Biopharma Holdings, Inc.

Healthcare Risk 29 · Moderate

Market implies +134.9%/yr vs model +15.0% · above model

Aspire Biopharma Holdings, Inc.

Deeply overvalued

Healthcare Risk 60 · High

Premium +75% Return to IV: -42.7%

Market implies +0.0%/yr vs model +15.0% · below model

ASSEMBLY BIOSCIENCES, INC.

Healthcare Risk 34 · Moderate

Discount 15% Return to IV: +18.3%

Market implies -2.5%/yr vs model +50.0% · below model

Ascendis Pharma A/S

Healthcare Risk 54 · Elevated

Limited data — see page

AtaiBeckley Inc.

Healthcare Risk 31 · Moderate

Market implies +63.5%/yr vs model +50.0% · above model

Alphatec Holdings, Inc.

Deeply undervalued

Healthcare Risk 48 · Elevated

Discount 68% Return to IV: +215.2%

Market implies -23.3%/yr vs model +33.1% · below model

Atara Biotherapeutics, Inc.

Healthcare Risk 39 · Moderate

Discount 4% Return to IV: +4.5%

Market implies -3.3%/yr vs model +15.0% · below model

aTYR PHARMA INC

Healthcare Risk 26 · Moderate

Market implies +82.5%/yr vs model +15.0% · above model

Aurinia Pharmaceuticals Inc.

Deeply undervalued

Healthcare Risk 33 · Moderate

Discount 62% Return to IV: +165.5%

Market implies +4.8%/yr vs model +25.0% · below model

Aura Biosciences, Inc.

Healthcare Risk 39 · Moderate

Limited data — see page

Autolus Therapeutics plc

Healthcare Risk 36 · Moderate

Market implies +34.2%/yr vs model +15.0% · above model

ArriVent BioPharma, Inc.

Healthcare Risk 31 · Moderate

Limited data — see page

Atea Pharmaceuticals, Inc.

Healthcare Risk 33 · Moderate

Market implies -2.4%/yr vs model +15.0% · below model

Avalyn Pharma Inc.

Healthcare Risk 51 · Elevated

Limited data — see page

Avalo Therapeutics, Inc.

Healthcare Risk 34 · Moderate

Market implies +142.3%/yr vs model +2.0% · above model

ANAVEX LIFE SCIENCES CORP.

Healthcare Risk 44 · Elevated

Limited data — see page

Axsome Therapeutics, Inc.

Healthcare Risk 42 · Elevated

Market implies +18.8%/yr vs model +15.0% · above model

AYTU BIOPHARMA, INC

Deeply undervalued

Healthcare Risk 28 · Moderate

Discount 76% Return to IV: +310.4%

Market implies -30.3%/yr vs model +2.0% · below model

ASTRAZENECA PLC

Limited data — see page

Industrials Risk 31 · Moderate

Market implies +34.3%/yr vs model +8.4% · above model

Healthcare Risk 33 · Moderate

Market implies +50.2%/yr vs model +15.0% · above model

Bone Biologics Corp

Healthcare Risk 33 · Moderate

Limited data — see page

Bone Biologics Corp

Healthcare Risk 37 · Moderate

Limited data — see page

Healthcare Risk 36 · Moderate

Market implies +65.3%/yr vs model +15.0% · above model

Bicara Therapeutics Inc.

Healthcare Risk 42 · Elevated

Limited data — see page

BioCardia, Inc.

Healthcare Risk 37 · Moderate

Market implies +64.2%/yr vs model +15.0% · above model

BIOCRYST PHARMACEUTICALS INC

Deeply undervalued

Healthcare Risk 28 · Moderate

Discount 84% Return to IV: +519.8%

Market implies -6.6%/yr vs model +25.0% · below model

BriaCell Therapeutics Corp.

Healthcare Risk 27 · Moderate

Limited data — see page

BriaCell Therapeutics Corp.

Healthcare Risk 28 · Moderate

Limited data — see page

BriaCell Therapeutics Corp.

Healthcare Risk 39 · Moderate

Limited data — see page

Biodexa Pharmaceuticals Plc

Healthcare Risk 52 · Elevated

Market implies +150.0%/yr vs model +15.0% · above model

Healthcare Risk 54 · Elevated

Premium +62% Return to IV: -38.2%

Market implies +1.2%/yr vs model +12.9% · below model

Black Diamond Therapeutics, Inc.

Deeply undervalued

Healthcare Risk 36 · Moderate

Discount 52% Return to IV: +106.5%

Market implies -6.3%/yr vs model +10.0% · below model

Beam Therapeutics Inc.

Healthcare Risk 42 · Elevated

Market implies +43.2%/yr vs model +28.1% · above model

BullFrog AI Holdings, Inc.

Healthcare Risk 33 · Moderate

Market implies +66.4%/yr vs model +15.0% · above model

BullFrog AI Holdings, Inc.

Healthcare Risk 36 · Moderate

Market implies +31.3%/yr vs model +15.0% · above model

BioNexus Gene Lab Corp

Healthcare Risk 50 · Elevated

Discount 22% Return to IV: +28.6%

Market implies -10.9%/yr vs model +2.0% · below model

Healthcare Risk 40 · Elevated

Market implies -50.0%/yr vs model +2.0% · below model

Bio Green Med Solution, Inc.

Deeply overvalued

Healthcare Risk 55 · Elevated

Premium +7% Return to IV: -6.3%

Market implies -9.8%/yr vs model +15.0% · below model

Healthcare Risk 37 · Moderate

Limited data — see page

bioAffinity Technologies, Inc.

Industrials Risk 33 · Moderate

Market implies +14.1%/yr vs model +15.0% · in line

Healthcare Risk 34 · Moderate

Model IV$249.04

Discount 13% Return to IV: +14.7%

Market implies +0.9%/yr vs model +3.0% · in line

BioAge Labs, Inc.

Healthcare Risk 33 · Moderate

Market implies +48.7%/yr vs model +15.0% · above model

Bioceres Crop Solutions Corp.

Basic Materials Risk 31 · Moderate

Limited data — see page

Healthcare Risk 29 · Moderate

Limited data — see page

Healthcare Risk 28 · Moderate

Limited data — see page

Black Hawk Acquisition Corp

Healthcare Risk 37 · Moderate

Limited data — see page

Black Hawk Acquisition Corp

Healthcare Risk 43 · Elevated

Limited data — see page

Black Hawk Acquisition Corp

Healthcare Risk 35 · Moderate

Limited data — see page

BIOLIFE SOLUTIONS INC

Healthcare Risk 31 · Moderate

Market implies +51.7%/yr vs model +2.0% · above model

Healthcare Risk 31 · Moderate

Limited data — see page

BELITE BIO, INC

Healthcare Risk 38 · Moderate

Limited data — see page

BlackRock Health Sciences Trust

Limited data — see page

Biomea Fusion, Inc.

Healthcare Risk 37 · Moderate

Limited data — see page

BlackRock Health Sciences Term Trust

Limited data — see page

BIOMARIN PHARMACEUTICAL INC

Deeply undervalued

Healthcare Risk 30 · Moderate

Discount 34% Return to IV: +52.1%

Market implies +5.1%/yr vs model +13.5% · below model